Funding for this research was provided by:
National Institute of Child Health and Human Development (HD036071)
Intellectual and Developmental Disabilities Research Center (U54HD079125)
Received: 22 May 2018
Accepted: 22 August 2018
First Online: 5 September 2018
Compliance with Ethical Standards
: RJH has received funding from Novartis, Roche/Genentech, Alcobra, and Neuren for treatment trials in fragile X syndrome, autism, and Down syndrome. She has also consulted with Novartis, Fulcrum, Zynerba, and Roche/Genentech regarding treatment for fragile X syndrome. The other authors have no conflicts of financial interest relevant to this article to disclose.